The author describes the results of treatment of 299 patients with clinical evidence of cerebral atherosclerosis receiving three groups of antiatherosclerotic agents: improving cerebral blood flow (naftidrofuryl, cinnarazine, pyridinol carbamate, low-molecular dextran), normalizing lipid metabolism (clofibrate, heparinoid, alpha-tocopherol, Procetophen) and improving the metabolism of nerve cells (piracetam, pyritinol). After a statistical analysis of the results of the author evaluated the effectiveness of these drugs in various groups and suggested practical conclusions and treatment schedules in various forms of cerebral atherosclerosis.